Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors ...Middle East

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In Global, For Global" collaboration strategy. NEWARK, Del. and NANJING, China, Feb. 3, 2026 /PRNewswire/ -- Biosion, Inc. ("Biosion"),...

Hence then, the article about biosion announces first patient dosed in investigator initiated phase 1 trial of bsi 082 a next generation anti sirpa monoclonal antibody for advanced solid tumors was published today ( Tuesday 03/02/2026 - 12:38 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors )

Also on site :

• Police: Two killed in shooting at West San Jose shopping center
• Judge Rules That ICE Agents Violate the Fourth Amendment by Making Arrests While Masked
• Google’s new 1.9GW clean energy deal includes massive 100-hour battery